Corrigendum to "In vitro susceptibilities of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia-Pacific region: 2004 results from SMART (Study for Monitoring Antimicrobial Resistance Trends)" [Int. J. Antimicrob. Agents 28 (2006) 238-243] (DOI:10.1016/j.ijantimicag.2006.04.010);In vitro susceptibilities of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia-Pacific region: 2004 results from SMART (Study for Monitoring Antimicrobial Resistance Trends)

International Journal of Antimicrobial Agents

Volumn 28, Issue 3, 2006, Pages 238-243

  Hsueh, Po Ren ^a   Snyder, Theresa A ^b   DiNubile, Mark J ^b   Satischandran, Vilas ^b   McCarroll, Kathleen ^b   Chow, Joseph W ^b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Carbapenems; Enterobacteriaceae; Extended spectrum lactamase (ESBL); Intra abdominal infections; SMART

Indexed keywords

ANTIINFECTIVE AGENT; CARBAPENEM; EXTENDED SPECTRUM BETA LACTAMASE;

ABDOMINAL INFECTION; ARTICLE; ASIA; BACTERIUM ISOLATION; ENTEROBACTERIACEAE; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; IN VITRO STUDY; INFECTION SENSITIVITY; NONHUMAN; PACIFIC ISLANDS; PRIORITY JOURNAL;

EID: 33747148060     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2008.12.003     Document Type: Erratum

References (14)

1. Paterson D.L., Rossi F., Baquero F., et al. In vitro susceptibilities of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: the 2003 Study for Monitoring Antimicrobial Resistance Trends (SMART). J Antimicrob Chemother 55 (2005) 965-973
2. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 6th ed. Approved Standard M7-A6. Villanova, PA: NCCLS; 2003.
3. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing. Thirteenth Informational Supplement. Supplemental Tables M100-S13. Villanova, PA: NCCLS; 2003.
4. Miettinen O., and Nurminen M. Comparative analysis of two rates. Stat Med 4 (1985) 213-226
5. Stürenburg E., and Mack D. Extended-spectrum β-lactamases: implications for the clinical microbiology laboratory, therapy, and infection control. J Infect 47 (2003) 273-295
6. Thompson K.S. Controversies about extended-spectrum and AmpC beta-lactamases. Emerg Infect Dis 7 (2001) 333-336
7. Hanson N.D. AmpC β-lactamases: what do we need to know for the future?. J Antimicrob Chemother 52 (2003) 2-4
8. Song W., Moland E.S., Hanson N.D., Lewis J.S., Jorgensen J.H., and Thomson K.S. Failure of cefepime therapy in treatment of Klebsiella pneumoniae bacteremia. J Clin Microbiol 43 (2005) 4891-4894
9. Komatsu M., Aihara M., Shimakawa K., et al. Evaluation of MicroScan ESBL confirmation panel for Enterobacteriaceae producing extended-spectrum β-lactamases isolated in Japan. Diagn Microbiol Infect Dis 46 (2003) 125-130
10. Stürenburg E., Sobottka I., Noor D., et al. Evaluation of a new cefepime-clavulanate ESBL Etest to detect extended-spectrum β-lactamases in an Enterobacteriaceae strain collection. J Antimicrob Chemother 54 (2004) 134-138
11. Queenan A.M., Foleno B., Gownley C., et al. Effects of inoculum and β-lactamase activity in AmpC- and extended-spectrum β-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae clinical isolates tested by using NCCLS ESBL methodology. J Clin Microbiol 42 (2004) 269-275
12. Decré D., Burghoffer B., Gautier V., et al. Outbreak of multi-resistant Klebsiella oxytoca involving strains with extended-spectrum β-lactamases and strains with extended-spectrum activity of the chromosomal β-lactamase. J Antimicrob Chemother 54 (2004) 881-888
13. Schwaber M.J., De-Medina T., and Carmeli Y. Epidemiological interpretation of antibiotic resistance studies-what are we missing?. Nat Rev Microbiol 2 (2004) 979-983
14. Finch R.G. Antibiotic resistance: a view from the prescriber. Nat Rev Microbiol 2 (2004) 989-994